IADR Abstract Archives
Bone preservation and recovery with Synthetic-Bone-Mineral (SBM) in osteoporotic rat.
Objectives: Osteoporosis, affecting over 54% US-population 50 year and older, is critically influenced by nutritional/mineral intake and estrogen levels. We hypothesize that dietary supplement of our Calcium-Phosphate based biomaterial(SBM) can prevent and reverse bone loss induced from both mineral and estrogen deficiencies.
Methods: To test our hypothesis, we used FDA approved estrogen and mineral deficient rat models. In our estrogen deficient model, thirty 3-month-old female Sprague Dawley rats were randomly assigned to 3 groups (n=10): ovariectomized (OVX), OVX on SBM supplement and Sham operated, all on mineral deficient diet (MD) for first 3 months. Supplement in SBM group was added to diet from the 4th month. In the mineral deficient model, sixty 6-month-old male and female rats were randomly assigned to receive one of three diets (n=10): basic diet (BD), MD or MD with SBM. All rats were sacrificed after 6 months and their femurs, vertebrae (L4, L5) and mandible harvested for x-ray radiography (µCT, Faxitron, Dexa) and mechanical property evaluation (Instron 5560, rate 1mm/min).
Results: Across study groups SBM significantly improved bone volume, density and mineral content. In the mandible, SBM preserved bone mineral density in the condyle (p<0.001), mandibular body (p<0.001), and alveolar bones (p=0.013) in both male and female rats. Critical areas of bone that are most susceptible to osteoporotic fractures (e.g. femoral neck, L4 L5 vertebrae) showed significant recovery of bone lost (p<0.05). Mechanical testing (three-point bending test) performed on rat femurs revealed that SBM group had significantly higher elastic modulus (p<0.05), flexural strength (p<0.05), compressive strength (p<0.001), and cortical thickness (p<0.05).
Conclusions: Our findings demonstrate that SBM administered orally can effectively prevent and recover systemic bone lost as a result of estrogen deficiency /or mineral deficiency irrespective of gender while demonstrating none of the side effects as seen in the current osteoporotic therapeutics.
Methods: To test our hypothesis, we used FDA approved estrogen and mineral deficient rat models. In our estrogen deficient model, thirty 3-month-old female Sprague Dawley rats were randomly assigned to 3 groups (n=10): ovariectomized (OVX), OVX on SBM supplement and Sham operated, all on mineral deficient diet (MD) for first 3 months. Supplement in SBM group was added to diet from the 4th month. In the mineral deficient model, sixty 6-month-old male and female rats were randomly assigned to receive one of three diets (n=10): basic diet (BD), MD or MD with SBM. All rats were sacrificed after 6 months and their femurs, vertebrae (L4, L5) and mandible harvested for x-ray radiography (µCT, Faxitron, Dexa) and mechanical property evaluation (Instron 5560, rate 1mm/min).
Results: Across study groups SBM significantly improved bone volume, density and mineral content. In the mandible, SBM preserved bone mineral density in the condyle (p<0.001), mandibular body (p<0.001), and alveolar bones (p=0.013) in both male and female rats. Critical areas of bone that are most susceptible to osteoporotic fractures (e.g. femoral neck, L4 L5 vertebrae) showed significant recovery of bone lost (p<0.05). Mechanical testing (three-point bending test) performed on rat femurs revealed that SBM group had significantly higher elastic modulus (p<0.05), flexural strength (p<0.05), compressive strength (p<0.001), and cortical thickness (p<0.05).
Conclusions: Our findings demonstrate that SBM administered orally can effectively prevent and recover systemic bone lost as a result of estrogen deficiency /or mineral deficiency irrespective of gender while demonstrating none of the side effects as seen in the current osteoporotic therapeutics.